Gagnon Advisors LLC reduced its position in shares of CareDx, Inc. (NASDAQ:CDNA - Free Report) by 47.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 286,889 shares of the company's stock after selling 260,004 shares during the quarter. CareDx accounts for approximately 10.2% of Gagnon Advisors LLC's investment portfolio, making the stock its biggest holding. Gagnon Advisors LLC owned approximately 0.55% of CareDx worth $18,648,000 at the end of the most recent reporting period.
Other large investors have also recently added to or reduced their stakes in the company. Lisanti Capital Growth LLC acquired a new position in shares of CareDx during the 3rd quarter worth about $8,463,000. Allspring Global Investments Holdings LLC raised its holdings in shares of CareDx by 4.4% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 23,000 shares of the company's stock valued at $1,523,000 after purchasing an additional 961 shares during the period. Ethic Inc. bought a new stake in shares of CareDx in the 3rd quarter valued at about $379,000. Alps Advisors Inc. acquired a new stake in CareDx in the 3rd quarter valued at about $720,000. Finally, Calamos Advisors LLC acquired a new stake in CareDx in the 3rd quarter valued at about $225,000.
Insiders Place Their Bets
In other CareDx news, CFO Keith Kennedy sold 61,961 shares of the firm's stock in a transaction that occurred on Thursday, November 5th. The shares were sold at an average price of $77.82, for a total transaction of $4,821,805.02. Following the completion of the sale, the chief financial officer directly owned 199,147 shares in the company, valued at $15,497,619.54. This trade represents a 23.73% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.40% of the stock is currently owned by corporate insiders.
CareDx Price Performance
Shares of CDNA opened at $79.81 on Friday. The firm has a market capitalization of $4.19 billion, a PE ratio of 122.99 and a beta of 2.51. The company's 50-day moving average is $65.78 and its 200-day moving average is $36.42. CareDx, Inc. has a fifty-two week low of $15.15 and a fifty-two week high of $90.87.
CareDx (NASDAQ:CDNA - Get Free Report) last posted its earnings results on Thursday, October 29th. The company reported $0.70 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.25 by $0.45. The company had revenue of $139.36 million during the quarter, compared to analysts' expectations of $121.96 million. CareDx had a net margin of 25.86% and a return on equity of 9.74%. CareDx's quarterly revenue was up 39.3% compared to the same quarter last year. During the same quarter last year, the company posted $0.03 EPS. Analysts predict that CareDx, Inc. will post 1.00 earnings per share for the current fiscal year.
Analysts Set New Price Targets
A number of research firms recently commented on CDNA. Canaccord Genuity Group set a $99.00 price target on CareDx in a report on Friday, October 30th. William Blair upgraded CareDx to a "hold" rating in a research note on Thursday, July 16th. Craig Hallum upgraded CareDx from a "hold" rating to a "buy" rating and set a $64.00 price objective on the stock in a research note on Monday, August 3rd. Wall Street Zen cut CareDx from a "strong-buy" rating to a "buy" rating in a research report on Saturday, October 31st. Finally, HC Wainwright reiterated a "neutral" rating and set a $46.00 target price on shares of CareDx in a research note on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, CareDx presently has a consensus rating of "Moderate Buy" and an average target price of $70.33.
Check Out Our Latest Analysis on CDNA
About CareDx
(
Free Report)
CareDx, Inc. is a precision medicine company focused on organ transplantation. It develops and provides diagnostic tests and related services to help clinicians assess transplant recipients and monitor their health over time. Its offerings include AlloSure, a donor-derived cell-free DNA test used to help monitor for organ rejection, and AlloMap, a gene-expression test used in heart transplant care. CareDx also provides histocompatibility testing, clinical tools, and services designed to support patients and transplant care teams.
Featured Stories
Want to see what other hedge funds are holding CDNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CareDx, Inc. (NASDAQ:CDNA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider CareDx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CareDx wasn't on the list.
While CareDx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.